Chikungunya - Pipeline Review, H1 2015

Published: Apr, 2015 | Pages: 75 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Chikungunya - Pipeline Review, H1 2015

Summary 

Global Markets Direct's, 'Chikungunya - Pipeline Review, H1 2015', provides an overview of the Chikungunya's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chikungunya, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chikungunya and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Chikungunya
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Chikungunya and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Chikungunya products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Chikungunya pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reason To Buy 

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Chikungunya
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Chikungunya pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Chikungunya Overview 9
Therapeutics Development 10
Pipeline Products for Chikungunya - Overview 10
Pipeline Products for Chikungunya - Comparative Analysis 11
Chikungunya - Therapeutics under Development by Companies 12
Chikungunya - Therapeutics under Investigation by Universities/Institutes 13
Chikungunya - Pipeline Products Glance 14
Clinical Stage Products 14
Early Stage Products 15
Unknown Stage Products 16
Chikungunya - Products under Development by Companies 17
Chikungunya - Products under Investigation by Universities/Institutes 18
Chikungunya - Companies Involved in Therapeutics Development 19
Abivax S.A. 19
Arbovax, Inc. 20
Bharat Biotech International Limited 21
Indian Immunologicals Limited 22
Inovio Pharmaceuticals, Inc. 23
Integral Molecular, Inc. 24
Merck & Co., Inc. 25
PaxVax 26
Profectus BioSciences, Inc. 27
Takeda Pharmaceutical Company Limited 28
Themis Bioscience GmbH 29
Chikungunya - Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Target 31
Assessment by Mechanism of Action 33
Assessment by Route of Administration 35
Assessment by Molecule Type 37
Drug Profiles 39
ABX-309 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Antibody for Chikungunya - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
chikungunya vaccine - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
chikungunya vaccine - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
chikungunya vaccine - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
chikungunya vaccine - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
chikungunya vaccine - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
chikungunya vaccine - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
chikungunya vaccine - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
chikungunya vaccine - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
chikungunya vaccine - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
chikungunya vaccine - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
chikungunya vaccine - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
chikungunya vaccine - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
chikungunya vaccine - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
chikungunya vaccine - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
DEF-201 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
IMCKV-063 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Monoclonal Antibodies for Chikungunya - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Monoclonal Antibodies to Inhibit CHIKV E2 for Chikungunya - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Monoclonal Antibodies to Inhibit Viral E1/E2 Proteins for Chikungunya - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
MV-CHIK - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Small Molecule to Inhibit NS2 and NS3 for Chikungunya - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Small Molecules to Inhibit Viral RNA for Chikungunya Virus Infections - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Chikungunya - Recent Pipeline Updates 65
Chikungunya - Dormant Projects 67
Chikungunya - Product Development Milestones 68
Featured News & Press Releases 68
Mar 02, 2015: Themis Bioscience's Chikungunya Vaccine Study Results Published in The Lancet Infectious Diseases 68
Nov 20, 2014: Themis Bioscience's Vaccine Against Chikunguya Successful In Phase 1 68
Aug 14, 2014: Experimental chikungunya vaccine induces robust antibody response 69
Jun 12, 2014: Threat of Emerging Virus can be Stopped: Interim results of First Clinical Trial of Themis Bioscience's Vaccine Candidate Against Chikungunya Fever Prove Successful 71
Mar 27, 2013: Themis Bioscience Plans To Initiate Phase I Study Of Chikungunya Fever Vaccine Candidate 71
Dec 20, 2011: NIAID Enrolls Participants In Chikungunya Vaccine Trial 72
Aug 15, 2011: Inviragen And University of Texas Medical Branch Receive Funding For Development Of Chikungunya Virus Vaccine 72
Nov 04, 2010: Novel Recombinant Chikungunya Virus Vaccine Shown To Be Safe And Effective In Multiple Animal Models 73
Nov 02, 2010: Inviragen Receives Two Therapeutic Discovery Project Grants For Vaccine Development 73
Appendix 74
Methodology 74
Coverage 74
Secondary Research 74
Primary Research 74
Expert Panel Validation 74
Contact Us 74
Disclaimer 75

List of Tables

Number of Products under Development for Chikungunya, H1 2015 10
Number of Products under Development for Chikungunya - Comparative Analysis, H1 2015 11
Number of Products under Development by Companies, H1 2015 12
Number of Products under Investigation by Universities/Institutes, H1 2015 13
Comparative Analysis by Clinical Stage Development, H1 2015 14
Comparative Analysis by Early Stage Development, H1 2015 15
Comparative Analysis by Unknown Stage Development, H1 2015 16
Products under Development by Companies, H1 2015 17
Products under Investigation by Universities/Institutes, H1 2015 18
Chikungunya - Pipeline by Abivax S.A., H1 2015 19
Chikungunya - Pipeline by Arbovax, Inc., H1 2015 20
Chikungunya - Pipeline by Bharat Biotech International Limited, H1 2015 21
Chikungunya - Pipeline by Indian Immunologicals Limited, H1 2015 22
Chikungunya - Pipeline by Inovio Pharmaceuticals, Inc., H1 2015 23
Chikungunya - Pipeline by Integral Molecular, Inc., H1 2015 24
Chikungunya - Pipeline by Merck & Co., Inc., H1 2015 25
Chikungunya - Pipeline by PaxVax, H1 2015 26
Chikungunya - Pipeline by Profectus BioSciences, Inc., H1 2015 27
Chikungunya - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 28
Chikungunya - Pipeline by Themis Bioscience GmbH, H1 2015 29
Assessment by Monotherapy Products, H1 2015 30
Number of Products by Stage and Target, H1 2015 32
Number of Products by Stage and Mechanism of Action, H1 2015 34
Number of Products by Stage and Route of Administration, H1 2015 36
Number of Products by Stage and Molecule Type, H1 2015 38
Chikungunya Therapeutics - Recent Pipeline Updates, H1 2015 65
Chikungunya - Dormant Projects, H1 2015 67